AKRO Akero Therapeutics Quick Ratio

Akero Therapeutics (AKRO) is developing treatments for metabolic pathologies through partnerships with clinics and laboratories. The expert team is expanding via stock options and the recruitment of specialized professionals. The critical solvency ratio on the GURU.Markets service daily chart shows that the current parameter equals 16.42. The brand's promising status is confirmed by the trust of scientists and success in trials of drugs for the therapy of liver diseases.

To assess the credit quality of Akero Therapeutics (AKRO), the analyst utilizes the quick ratio history, which demonstrates the company's ability to instantaneously settle short-term liabilities using cash and accounts receivable, excluding slow-moving inventories. A high level of this metric guarantees the financial stability of Akero Therapeutics, ensuring uninterrupted funding for the development of breakthrough liver fibrosis therapies and minimizing the risk of cash flow gaps.